OBJECTIVES: The risk of blindness from glaucoma can be reduced by early detection and treatment. A domestic large-scale surveillance (Tajimi Study) shows that approximately 90% of glaucoma patients of 40 years or older are undiagnosed, and initiation of the treatment is delayed. In this study the glaucoma treatment was investigated to understand the real-world situation of glaucoma therapy using claim data in Japan. METHODS: This was a retrospective cohort study. The data were extracted from a Japanese healthcare database (MinaCare Co., Ltd), which contained claim data obtained from approximately 2.0 million members of employment-based health insurance groups and their dependents. The ICD-10 classification was used to identify glaucoma patients. A washout period of 6 months before enrollment was set during which there were no records of prescriptions of antiglaucoma drugs or glaucoma surgery. Antiglaucoma ophthalmic solutions or surgery for initial treatment, persistence and change in medication were investigated. RESULTS: Out of 2,074,499 people in the database as of August 2014, we identified 42,470 glaucoma patients and the target group who met the wash-out conditions involved 6,333 patients (male: 3,618; female: 2,715). About 75% of the patients were between 40 to 69 years old and about 10% were 70 years or older. Regarding the initial treatment, most patients started with topical antiglaucoma treatment and only 24 patients underwent surgery. The first prescription of antiglaucoma drug included 1 agent in 87%, and cases with 2 agents (10%), 3 agents (3%), or more than 3 agents (0.3%) were also identified. The most prescribed one was latanoprost (26%) followed by tafluprost (17%), and carteolol (10%). CONCLUSIONS: In this study, the initial treatment in most of the patients followed the treatment guidelines. However, lack of disease awareness among potential patients and accessibility to early screening and diagnosis of glaucoma may exist, and it should be given sufficient consideration.OBJECTIVES: Psoriasis (PSO) and psoriatic arthritis (PsA) are immune-mediated systemic inflammatory diseases; adalimumab (ADA) and etanercept (ETN) are among the most commonly used first-line biologic agents. As per FDA-approved dosage and administration, newly initiated PSO patients receive a higher loading dose followed by a regular maintenance dose. In clinical practice, however, patients may receive higher than recommended (increased) doses even during the maintenance phase of treatment. Given linear pricing of these medications, our objective was to determine if the increased dosing schedule increases payer costs and to what degree. METHODS: Continuously enrolled adult patients with ≥ 2 outpatient diagnoses of PSO (ICD-9 code: 696.1) or PsA (ICD-9 code: 696.0) were selected from the Symphony PTD Claims Database if their first biologic prescription date (index date) fell between May 2010 and April 2013. Patients were required to be treatment-naïve only to ADA or ETN pre-index. The cost analysis took place over 12 months po...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.